Francisco A. A. F. Gadelha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco A. A. F. Gadelha has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Celidarque da Silva Dias
Departamento de Ciências Farmacêuticas, Universidade Federal da Paraíba, João Pessoa, Brazil
1 shared publication - Damião Pergentino de Sousa
Laboratory of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences Federal University of Paraíba João Pessoa Paraíba Brazil
1 shared publication - Diogo Vilar da Fonsêca
Universidade Federal do Vale do São Francisco
1 shared publication - H. N. S. N. Pereira
Universidade Federal do Vale do São Francisco, Brasil
1 shared publication - Humberto de Carvalho Aragão Neto
Universidade Federal da Paraíba
1 shared publication - Jaime Ribeiro-Filho
Oswaldo Cruz Foundation (Fiocruz), Fiocruz Ceará, Eusébio 61773-270, CE, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 85, e286667
Umbelliferone presents orofacial antinociceptive and anti-inflammatory activity via reduction of TNF-α in mice
Pain is a normal response of the central nervous system to trauma, infections, neoplasms, neuropathies, and inflammation. It can arise from physical, emotional, or cognitive conditions, and is classified as orofacial pain when it affects the mouth and face. Umbelliferone, a coumarin from the umbelliferous plant family, is an important component of essential oils, and possesses antioxidant, curative, anti-inflammatory, and anti-tumor activity. The aim of this study was to investigate the orofacial antinociceptive and anti-inflammatory effects of umbelliferone in Swiss male mice Mus musculus, at 3 months of age. Test groups received different doses of umbelliferone (25, 50, or 75 mg/kg, i.p.). The negative control received 0.9% sodium chloride and Tween 80, with the positive control receiving morphine (5 mg/kg, i.p.) or dexamethasone (2 mg/kg, s.c.). We observed a significant reduction in acetic acid-induced abdominal writhing (p<0.001), and a decrease in paw licking in the orofacial nociception test with formalin (p < 0.01). The 50 and 75 mg/kg doses of umbelliferone presented significant reductions in the glutamate (p<0.01) and capsaicin (p<0.01) tests, suggesting activity on glutamatergic receptors and TRPV1. In the carrageenan-induced paw edema test (1%), there was a decrease in limb volume over 240 minutes (p<0.01), suggesting inhibition of the inflammatory process. There was also a reduction in leukocyte count (p<0.001) and TNF-α levels (p<0.001) when compared to the control group, being similar to the animals treated with dexamethasone (p<0.001). It was concluded that umbelliferone exhibits orofacial antinociceptive activity and anti-inflammatory activity via TNF-α. However, further preclinical studies are needed for a better characterization.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 85, e286667
Open AccessUmbelliferone presents orofacial antinociceptive and anti-inflammatory activity via reduction of TNF-α in mice
Pain is a normal response of the central nervous system to trauma, infections, neoplasms, neuropathies, and inflammation. It can arise from physical, emotional, or cognitive conditions, and is classified as orofacial pain when it affects the mouth and face. Umbelliferone, a coumarin from the umbelliferous plant family, is an important component of essential oils, and possesses antioxidant, curative, anti-inflammatory, and anti-tumor activity. The aim of this study was to investigate the orofacial antinociceptive and anti-inflammatory effects of umbelliferone in Swiss male mice Mus musculus, at 3 months of age. Test groups received different doses of umbelliferone (25, 50, or 75 mg/kg, i.p.). The negative control received 0.9% sodium chloride and Tween 80, with the positive control receiving morphine (5 mg/kg, i.p.) or dexamethasone (2 mg/kg, s.c.). We observed a significant reduction in acetic acid-induced abdominal writhing (p<0.001), and a decrease in paw licking in the orofacial nociception test with formalin (p < 0.01). The 50 and 75 mg/kg doses of umbelliferone presented significant reductions in the glutamate (p<0.01) and capsaicin (p<0.01) tests, suggesting activity on glutamatergic receptors and TRPV1. In the carrageenan-induced paw edema test (1%), there was a decrease in limb volume over 240 minutes (p<0.01), suggesting inhibition of the inflammatory process. There was also a reduction in leukocyte count (p<0.001) and TNF-α levels (p<0.001) when compared to the control group, being similar to the animals treated with dexamethasone (p<0.001). It was concluded that umbelliferone exhibits orofacial antinociceptive activity and anti-inflammatory activity via TNF-α. However, further preclinical studies are needed for a better characterization.
- 28 January 2022
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 32 (1) , 111-121
Curine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Downregulating the TLR4/MD-2/NF-κB(p65) Signaling Pathway
- 28 January 2022
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 32 (1) , 111-121
Curine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Downregulating the TLR4/MD-2/NF-κB(p65) Signaling Pathway